Suven Life Sciences today said it has received five product patents for their drug in Europe, Hong Kong, Israel, Australia and Norway for the treatment of disorders associated with neuro-degenerative diseases.
“The grant of 1 product patent from Australia, one from Europe, one from Hong Kong, one from Israel and one from Norway corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases,” Suven Life Sciences said in a BSE filing.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven, it added.
The compounds are being developed as therapeutic agents and are useful in treatment of cognitive impairment associated with neuro-degenerative disorders such as Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia, it said.
With these new patents, Suven has a total of 21 granted patents from Australia, 15 from Europe, 16 from Hong Kong, four from Israel and five from Norway.
These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts.
Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II, the firm said.
Suven Life Sciences shares were trading 0.12 per cent down at Rs 299.85 apiece at 1130 hours on the BSE.